Piper Jaffray Now Rates Merck At “Hold” — Target $60

This came out last Thursday while I was attending to other professional duties.

Some of the analysts’ froth around Merck’s near term growth has waned — now that the sitagliptin franchise is slowing and prembrolizumab is being mightily pressed at roll out by BMS’s nivolumab.

. . . .Target: $60

Rated: Hold. . . .

I still see Merck as a solid long term play, even at today’s relatively fullsome prices. So, there you have it. Onward — with a smile.


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: